SlideShare a Scribd company logo
REPRODUCTIVE
TOXICOLOGY STUDIES
OECD GUIDELINES :422
Prepared by: SONAL. VIJAY. PANDE
M Pharm sem 2
Department : pharmacology
WHAT IS REPRODUCTIVE TOXICOLOGY?
 Reproductive toxicity refers to structural and functional alterations that affect
reproductive system in sexually mature males and females.
 Reproductive toxicity includes effects on male fertility and female fertility and
lactation.
Two major class:
• Reproductive toxicity -Effects on sexual behavior and fertility in
males and non-pregnant females
• Developmental toxicity-abnormal structure or functional
development following exposure of pregnant or lactating females
INTRODUCTION
ESTROUS CYCLE: Reproductive cycle of female, generally defined as
period from one estrus to the next.
ESTRUS: Period of sexual receptivity.
• Commonly referred to as “Heat”
ANESTRUS: Period when female does not experience cycles
• Occurs during pregnancy.
Polyestrus: Uniform distribution of estrous cycles which occur
regularly throughout the year eg: rodents, cattle
Monoestrus: – One cycle per year
Eg: dogs, wolf,bears
Estrous cycle
Follicular
phase
Luteal phase
Begins during
luteolysis
Ends at ovulation
Proestrus
Estrus
Begins during
ovulation
Ends at luteolysis
Metestrus
Diestrus
The oestrous cycle consists of four stages:
1.Prooestrus
2.oestrus
3.metestrus (or dioestrus 1)
4.dioestrus (or dioestrus 2).
• Because rats are continuously polyoestrous (i.e., cycle constantly throughout the year)
dioestrus is immediately followed by the prooestrus phase of the next cycle
• Anoestrus, a period of reproductive quiescence between oestrous cycles, is thus not
usually observed in healthy, cycling female rats.
• Oestrous cyclicity only ceases during pseudopregnancy, pregnancy, and lactation,
although a fertile postpartum oestrus does occur within 24 hours after birth.
Proestrus
• Begins when progesterone declines(luteolysis:regression of corpus luteum ) and ends
at onset of estrus
• Lasts 2 to 5 days
Estrus
• Period of sexual receptivity • Large increase in estrogen
Metestrus:
↑Increase in progesterone, ↆ decrease in estrogen • Endometrial lining thickens and
uterine muscles show increased development.
Diestrus:
Relatively short period of time between estrous cycles during the breeding season of
polyestrous animals – No reproductive activity
• Sexual maturity in female rats usually occurs between 30 and 50 days of age.
• The occurrence of vaginal opening (VO) and first oestrus, as 38 days.
• The first oestrous cycle begins within approximately one week after vaginal
opening and recurs regularly every 4 or 5 days for a variable proportion of the
animal’s lifespan, depending on the strain of rat.
duration of an ovarian cycle can vary:
4 days: mice, rats and hamsters
16 days: guinea pigs
28 days: humans
Combined repeated dose toxicity study with the
reproduction/developmental toxicity screening test
OECD guideline for testing of chemicals on reproductive
toxicology
PRINCIPLE OF THE TEST:
 The test chemical is administered in graduated doses to several groups
of males and females.
 Males should be dosed for a minimum of four weeks and up to and
including the day before scheduled kill
 pre-mating dosing period in males, fertility may not be a particular
sensitive indicator of testicular toxicity.
 Therefore, a detailed histological examination of the testes is essential.
 Histopathology of the male gonads, is considered sufficient to enable
detection of the majority of effects on male fertility and spermatogenesis.
 Females should be dosed throughout the study.
 This includes mating, the duration of pregnancy and at least thirteen days
after delivery, up to and including the day before scheduled kill.
 Duration of study, following acclimatisation and pre-dosing oestrous
cycle evaluation, is dependent on the female performance and is
approximately 63 day. [at least 14 days pre-mating, (up to) 14 days mating, 22 days gestation, 13 days lactation].
DESCRIPTION OF THE METHOD
Selection of animal species
Guideline is designed for use with the rat. The rat was the only species used.
The test animals should be characterized as to species, strain, sex, weight and
age.
Weight variation of animals used should be minimal and not exceed 20% of the
mean weight of each sex.
 Animals from the same strain and source are used in both studies.
HOUSING AND FEEDING
 The temperature in the experimental animal room should be 22º C (±
3). relative humidity should be at least 30%
 Lighting should be artificial, the photoperiod being 12 hours light, 12
hours dark.
 For feeding, laboratory diets used with an unlimited supply of drinking
water.
 no more than five animals should be housed per cage.
 Pregnant females should be caged individually and provided with nesting
materials.
 Lactating females will be caged individually with their offspring.
PREPARATION OF THE ANIMALS
 Healthy young adult animals are randomly assigned to the control and
treatment groups.
 Cages should be arranged in such a way that possible effects due to cage
placement are minimized.
 The animals are uniquely identified and kept in their cages for at least five
days prior to the start of the study to allow for acclimatisation to the laboratory
conditions.
PREPARATION OF DOSES
The test chemical be administered orally unless other routes of administration are
considered more appropriate. When the oral route is selected, the test chemical is
usually administered by gavage.
The test chemical is dissolved or suspended in a suitable vehicle.
PROCEDURE:
 Number and sex of animals
• It is recommended that each group be started with at least 10 males and 12-13
females.
 Dosage
• Generally, at least three test groups and a control group should be used.
• Dose levels may be based on information from acute toxicity tests or on
results from repeated dose studies.
• If a vehicle is used in administering the test chemical, the control group
should receive the vehicle in the highest volume used.
• Dose levels should be selected taking into account any existing toxicity
and (toxico-) kinetic data available.
• It should also be taken into account that there may be differences in sensitivity
between pregnant and non-pregnant animals.
• The highest dose level should be chosen with the aim of inducing toxic effects but
not death nor obvious suffering.
• Thereafter, a descending sequence of dose levels should be selected with a view to
demonstrating any dosage related response and no adverse effects at the lowest dose
level.
• Two- to four- fold intervals are frequently optimum and addition of a fourth test
group is often preferable to using very large intervals (e.g. more than a factor of 10)
between dosages.
Administration of doses
• The animals are dosed with the test chemical daily for 7 days a week.
• The volume should not exceed 1 ml/100 g body weight, except in the case of aqueous
solutions where 2 ml/100 g body weight may be used.
• Except for irritating or corrosive test chemicals which will normally reveal
exacerbated effects with higher concentrations, variability in test volume should be
minimized by adjusting the concentration to ensure a constant volume at all dose
levels.
• For test chemical administered via the diet or drinking water, it is important to ensure
that the quantities of the test chemical involved do not interfere with normal nutrition
or water balance.
EXPERIMENTAL SCHEDULE
EXPERIMENTAL SCHEDULE
 Dosing of both sexes should begin at least 2 weeks prior to mating, after they
have been acclimatised for at least five days and females have been screened for
normal oestrous cycles.
 The study should be scheduled in such a way that oestrous cycle evaluation
begins soon after the animals have attained full sexual maturity.
 This may vary slightly for different strains of rats in different laboratories, e.g.
Sprague Dawley rats 10 weeks of age, Wistar rats about 12 weeks of age
 Dams with offspring should be killed on day 13 post-partum, or shortly
thereafter. In order to allow for overnight fasting of dams prior to blood
collection (if this option is preferred), dams and their offspring need not
necessarily be killed on the same day.
 The day of birth (viz. when parturition is complete) is defined as day 0 post-
partum
 Dosing is continued in both sexes during the mating period.
 Males should further be dosed after the mating period at least until the
minimum total dosing period of 28 days has been completed
 They are then killed, or, alternatively, are retained and continued to be dosed
for the possible conduction of a second mating if considered appropriate.
 Daily dosing of the parental females should continue throughout pregnancy.
Mating procedure: Normally, 1:1 (one male to one female) matings should be
used in this study.
 Each morning the females should be examined for the presence of sperm or
a vaginal plug.
 Day 0 of pregnancy is defined as the day on which mating evidence is
confirmed
IN LIFE OBSERVATIONS
Clinical observation:
 Throughout the test period, general clinical observations should be made at
least once a day, and more frequently when signs of toxicity are observed.
 They should be made preferably at the same time(s) each day. all signs of
toxicity, including mortality, should be recorded.
 These records should include time of onset, degree and duration of toxicity
signs.
Body weight and food/water consumption
 Males and females should be weighed on the first day of dosing, at least weekly
thereafter, and at termination.
 During pregnancy, females should be weighed on days 0, 7, 14 and 20.
Oestrous cycles
 Oestrous cycles should be monitored before treatment starts to select for the
study females with regular cycle.
 Vaginal smears should also be monitored daily from the beginning of the
treatment period until evidence of mating. If there is concern about acute stress
effects that could alter oestrous cycles.
Offspring parameters:
 The duration of gestation should be recorded and is calculated
from day 0 of pregnancy.
 Any abnormal behaviour of the offspring should be recorded.
Clinical biochemistry
 Blood samples from a defined site are taken.
 Plasma samples specifically for hormone determination should be
obtained at a comparable time of the day.
 The numerical value obtained when analysing hormone
concentration.
Pathology
Gross necropsy :
 At the time of sacrifice or death during the study, the adult animals
should be examined macroscopically for any abnormalities or
pathological changes.
 Vaginal smears should be examined in the morning on the day of
necropsy to determine the stage of the oestrous cycle and
histopathology of ovaries.
 The testes and epididymides of all male adult animals should be
weighed.
Histopathology:
 Histological examination should be performed on the ovaries, testes and
epididymides of the animals of the highest dose group and the control
group.
DATA AND REPORTING
• Individual animal data should be provided.
• Additionally, all data should be summarised in tabular form, showing for each
test group the number of animals at the start of the test, the number of animals
found dead during the test or killed
• The time of any death or humane kill, the number of fertile animals, the number
of pregnant females,
• the number of animals showing signs of toxicity, a description of the signs of
toxicity observed.
Evaluation of results:
• The findings of this toxicity study should be evaluated in terms of
the observed effects, necropsy and microscopic findings.
Test report :
 Test chemical:
- source, limit date for use, if available stability of the test chemical
physical appearance, water solubility, and additional relevant
physicochemical properties; Vehicle
 Test animals:
o species/strain used;
o number, age and sex of animals;
o source, housing conditions, diet, etc.;
o individual weights of animals at the start of the test.
 Results:
o body weight/body weight changes;
o food consumption, and water consumption if available;
o toxic response data by sex and dose, including fertility, gestation, and any
other signs of toxicity;
FEMALE REPRODUCTIVE
TOXICITY STUDY
ICH S5(R3)
SCHEDULE Y
FEMALE FERTILITY TEST
• Drugs administered to both males (28days)and female (14 days) before mating
Segment I : Fertility and general reproductive performance study
Segment II: Teratogenicity
Segment III: Prenatal and post-natal study perinatal : fertility and early
embryonic development
FEMALE FERTILITY STUDY (SEGMENT I):
• The study should be done in one rodent species (rat preferred).
• The drug should be administered to both males and females, beginning a
sufficient number of days (28 days in males and 14 days in females) before
mating.
• Drug treatment should continue during mating and, subsequently, during the
gestation period.
• Three graded doses should be used, the highest dose (usually the MTD
obtained from previous systemic toxicity studies) should not affect general
health of the parent animals, At least 15 males and 15 females should be used
per dose group.
• Control and the treated groups should be of similar size.
• The route of administration should be the same as intended for therapeutic use
•Dams should be allowed to litter and their medication should be
continued till the weaning of pups.
• Observations on body weight, food intake, clinical signs of
intoxication, mating behaviour, progress of gestation! parturition
periods, length of gestation, parturition, post-partum health and gross
pathology (and histopathology of affected organs) of dams should be
recorded.
•The pups from both treated and control groups should be
observed for general signs of intoxication, sex-wise
distribution in different treatment groups, body weight, growth
parameters, survival, gross examination, and autopsy.
•Histopathology of affected organs should be done.
STUDY DESIGN
SEGMENT II:Teratogenicity
PERINATAL STUDY (SEGMENT III):
• This study is specially recommended if the drug is to be given to pregnant or
nursing mothers for long periods or where there are indications of possible
adverse effects on foetal development.
• One rodent species (preferably rat) is needed. Dosing at levels comparable to
multiples of human dose should be done by the intended clinical route.
• At least 4 groups (including control), each consisting of 15 dams should be
used.
• The drug should be administered throughout the last trimester of pregnancy
(from day 15 of gestation) and then the dose that causes low foetal loss should
be continued throughout lactation and weaning.
• Dams should then be sacrificed and examined as described below.
• One male and one female from each litter of Fl generation (total 15 males and 15
females in each group) should be selected at weaning and treated with vehicle or
test substance (at the dose levels described above) throughout their periods of
growth to sexual maturity, pairing, gestation, parturition and lactation.
• Mating performance and fertility of FI generation should thus be. evaluated to
obtain the F2 generation whose growth parameters should be monitored till
weaning.
• The criteria of evaluation should be the same as described earlier.
• Animals should be sacrificed at the end of the study and the observation
parameters should include (Dams) body weight, food intake, general signs of
intoxication, progress of gestation / parturition periods and gross pathology (if
any);andfor pups, the clinical signs, sex-wise distribution in dose groups, body
weight, growth parameters, gross examination, survival and autopsy (if
needed) and where necessary, histopathology.
Study design
• Estrous female rats at 10 to 11 weeks of age were cohabited overnight with a
single male.
• The next morning, females with sperm in their vaginal smears were regarded
as pregnant, and this day was designated as day 0 of gestation.
• Once insemination was confirmed, the females were weighed and randomly
allocated to six experimental groups.
• The dams were allowed to deliver naturally and nurse their pups until
postnatal day (PND) 21.
• On PND 0 (the day of birth), all pups were weighed and their sex was
determined, and the litters were culled randomly to eight (four pups/sex/ litter
when possible)
PROCEDURE
• In the present study, three to five males and three to five females per litter were
used.
• All neonates were given daily gavage administration of 12.5, 25, 50, or 100
mg/kg genistein.
• The measurement of sexual organ weight and histopathologic observation of the
reproductive tracts were performed
THANK YOU

More Related Content

What's hot

test item characterization of regulatory of toxicological studies
test item characterization of regulatory of toxicological studies test item characterization of regulatory of toxicological studies
test item characterization of regulatory of toxicological studies
SonaliJain736101
 
TEST ITEM CHARACTERIZATION IN REGULATORY TOXICOLOGY STUDIES.pptx
TEST ITEM CHARACTERIZATION IN REGULATORY TOXICOLOGY STUDIES.pptxTEST ITEM CHARACTERIZATION IN REGULATORY TOXICOLOGY STUDIES.pptx
TEST ITEM CHARACTERIZATION IN REGULATORY TOXICOLOGY STUDIES.pptx
ashharnomani
 
Ind enabling studies.
Ind enabling studies.Ind enabling studies.
Ind enabling studies.
Shikha Choudhary
 
Assignment on Toxicokinetics
Assignment on ToxicokineticsAssignment on Toxicokinetics
Assignment on Toxicokinetics
Deepak Kumar
 
Alternative methods to animal toxicity testing
Alternative methods to        animal toxicity testingAlternative methods to        animal toxicity testing
Alternative methods to animal toxicity testing
Sachin Sharma
 
Regulatory guidelines for conducting toxicity studies
Regulatory guidelines for conducting toxicity studiesRegulatory guidelines for conducting toxicity studies
Regulatory guidelines for conducting toxicity studies
HimikaRathi
 
Schedule y for toxicity studies
Schedule y  for toxicity studiesSchedule y  for toxicity studies
Schedule y for toxicity studiesKrushangiShah233
 
IND Enabling Studies by Kashikant Yadav
IND Enabling Studies by Kashikant YadavIND Enabling Studies by Kashikant Yadav
IND Enabling Studies by Kashikant Yadav
Kashikant Yadav
 
Acute inhalational toxicity studies.pptx
 Acute inhalational toxicity studies.pptx Acute inhalational toxicity studies.pptx
Acute inhalational toxicity studies.pptx
Tanuj Silori
 
Safety pharmacology studies
Safety pharmacology studies Safety pharmacology studies
Safety pharmacology studies
Santosh Sai
 
TOXICOKINETICS EVALUATION IN PRECLINICAL STUDIES.pptx
TOXICOKINETICS EVALUATION IN PRECLINICAL STUDIES.pptxTOXICOKINETICS EVALUATION IN PRECLINICAL STUDIES.pptx
TOXICOKINETICS EVALUATION IN PRECLINICAL STUDIES.pptx
Anmolkanda06
 
Alternative methods to animal toxicity testing
Alternative methods to animal toxicity testingAlternative methods to animal toxicity testing
Alternative methods to animal toxicity testing
Sanchit Dhankhar
 
Inhalation Toxicity Studies- OECD guidelines
 Inhalation Toxicity Studies- OECD guidelines Inhalation Toxicity Studies- OECD guidelines
Inhalation Toxicity Studies- OECD guidelines
Cerin Philip
 
Dermal Irritation and Dermal Toxicity Studies
Dermal Irritation and Dermal Toxicity Studies Dermal Irritation and Dermal Toxicity Studies
Dermal Irritation and Dermal Toxicity Studies
Dinesh Gangoda
 
Acute dermal toxicity-402
Acute dermal toxicity-402Acute dermal toxicity-402
Acute dermal toxicity-402
Dr Ajay Mandal
 
hERG Assay
hERG Assay hERG Assay
hERG Assay
VanarajRabari
 
Reproductive toxicity studies
Reproductive toxicity studiesReproductive toxicity studies
Reproductive toxicity studies
Loveinder Bhardwaj
 
Herg assay,Structure, Various screening methods and Advantages
Herg assay,Structure,  Various screening methods and AdvantagesHerg assay,Structure,  Various screening methods and Advantages
Herg assay,Structure, Various screening methods and Advantages
Urvashi Shakarwal
 
Safety pharmacology
Safety pharmacologySafety pharmacology
Safety pharmacology
Grandhi sandeep ganesh
 
Importance of guidelines in regulatory toxicity testing
Importance of guidelines in regulatory toxicity testingImportance of guidelines in regulatory toxicity testing
Importance of guidelines in regulatory toxicity testing
Chander K Negi
 

What's hot (20)

test item characterization of regulatory of toxicological studies
test item characterization of regulatory of toxicological studies test item characterization of regulatory of toxicological studies
test item characterization of regulatory of toxicological studies
 
TEST ITEM CHARACTERIZATION IN REGULATORY TOXICOLOGY STUDIES.pptx
TEST ITEM CHARACTERIZATION IN REGULATORY TOXICOLOGY STUDIES.pptxTEST ITEM CHARACTERIZATION IN REGULATORY TOXICOLOGY STUDIES.pptx
TEST ITEM CHARACTERIZATION IN REGULATORY TOXICOLOGY STUDIES.pptx
 
Ind enabling studies.
Ind enabling studies.Ind enabling studies.
Ind enabling studies.
 
Assignment on Toxicokinetics
Assignment on ToxicokineticsAssignment on Toxicokinetics
Assignment on Toxicokinetics
 
Alternative methods to animal toxicity testing
Alternative methods to        animal toxicity testingAlternative methods to        animal toxicity testing
Alternative methods to animal toxicity testing
 
Regulatory guidelines for conducting toxicity studies
Regulatory guidelines for conducting toxicity studiesRegulatory guidelines for conducting toxicity studies
Regulatory guidelines for conducting toxicity studies
 
Schedule y for toxicity studies
Schedule y  for toxicity studiesSchedule y  for toxicity studies
Schedule y for toxicity studies
 
IND Enabling Studies by Kashikant Yadav
IND Enabling Studies by Kashikant YadavIND Enabling Studies by Kashikant Yadav
IND Enabling Studies by Kashikant Yadav
 
Acute inhalational toxicity studies.pptx
 Acute inhalational toxicity studies.pptx Acute inhalational toxicity studies.pptx
Acute inhalational toxicity studies.pptx
 
Safety pharmacology studies
Safety pharmacology studies Safety pharmacology studies
Safety pharmacology studies
 
TOXICOKINETICS EVALUATION IN PRECLINICAL STUDIES.pptx
TOXICOKINETICS EVALUATION IN PRECLINICAL STUDIES.pptxTOXICOKINETICS EVALUATION IN PRECLINICAL STUDIES.pptx
TOXICOKINETICS EVALUATION IN PRECLINICAL STUDIES.pptx
 
Alternative methods to animal toxicity testing
Alternative methods to animal toxicity testingAlternative methods to animal toxicity testing
Alternative methods to animal toxicity testing
 
Inhalation Toxicity Studies- OECD guidelines
 Inhalation Toxicity Studies- OECD guidelines Inhalation Toxicity Studies- OECD guidelines
Inhalation Toxicity Studies- OECD guidelines
 
Dermal Irritation and Dermal Toxicity Studies
Dermal Irritation and Dermal Toxicity Studies Dermal Irritation and Dermal Toxicity Studies
Dermal Irritation and Dermal Toxicity Studies
 
Acute dermal toxicity-402
Acute dermal toxicity-402Acute dermal toxicity-402
Acute dermal toxicity-402
 
hERG Assay
hERG Assay hERG Assay
hERG Assay
 
Reproductive toxicity studies
Reproductive toxicity studiesReproductive toxicity studies
Reproductive toxicity studies
 
Herg assay,Structure, Various screening methods and Advantages
Herg assay,Structure,  Various screening methods and AdvantagesHerg assay,Structure,  Various screening methods and Advantages
Herg assay,Structure, Various screening methods and Advantages
 
Safety pharmacology
Safety pharmacologySafety pharmacology
Safety pharmacology
 
Importance of guidelines in regulatory toxicity testing
Importance of guidelines in regulatory toxicity testingImportance of guidelines in regulatory toxicity testing
Importance of guidelines in regulatory toxicity testing
 

Similar to Reproductive toxicology studies ACCORDING TO OECD guidlines 422

Reproductive toxicology
Reproductive toxicologyReproductive toxicology
Reproductive toxicology
Aanchal46
 
Reproductive toxicology
Reproductive toxicologyReproductive toxicology
Reproductive toxicology
Khadga Raj
 
REPRODUCTIVE TOXICITY STUDIE OF MALE AND FEMALEpptx
REPRODUCTIVE TOXICITY  STUDIE OF MALE AND FEMALEpptxREPRODUCTIVE TOXICITY  STUDIE OF MALE AND FEMALEpptx
REPRODUCTIVE TOXICITY STUDIE OF MALE AND FEMALEpptx
manishaJyala2
 
DOC-20220404-WA0001..pptx
DOC-20220404-WA0001..pptxDOC-20220404-WA0001..pptx
DOC-20220404-WA0001..pptx
SiddharthShekharSing4
 
OECD guidelines-Organisation for Economic Co-operation and Development guidel...
OECD guidelines-Organisation for Economic Co-operation and Development guidel...OECD guidelines-Organisation for Economic Co-operation and Development guidel...
OECD guidelines-Organisation for Economic Co-operation and Development guidel...
Hemadharshini Senthill
 
Teratogenicity.pptx
Teratogenicity.pptxTeratogenicity.pptx
Teratogenicity.pptx
ashharnomani
 
Female reproductive toxicity studies.pptx
Female reproductive toxicity studies.pptxFemale reproductive toxicity studies.pptx
Female reproductive toxicity studies.pptx
ashharnomani
 
teratogenic anu-3.pptx
teratogenic anu-3.pptxteratogenic anu-3.pptx
teratogenic anu-3.pptx
SiddharthShekharSing4
 
Subacute toxicity testing as per oecd guidelines tulsi 407
Subacute toxicity testing as per oecd guidelines tulsi 407Subacute toxicity testing as per oecd guidelines tulsi 407
Subacute toxicity testing as per oecd guidelines tulsi 407
Tulsi Gulabrao Patil
 
OECD Guideline 420: Acute oral Toxicity - Fixed Dose Procedure
OECD Guideline 420: Acute oral Toxicity - Fixed Dose ProcedureOECD Guideline 420: Acute oral Toxicity - Fixed Dose Procedure
OECD Guideline 420: Acute oral Toxicity - Fixed Dose Procedure
KhushbooThakur15
 
Sub acute
Sub acuteSub acute
Reproductive toxicology studies
Reproductive toxicology studiesReproductive toxicology studies
Reproductive toxicology studies
kusuma khushi
 
IN-VIVO CARCINOGENICITY STUDIES.pptx TG451
IN-VIVO CARCINOGENICITY STUDIES.pptx TG451IN-VIVO CARCINOGENICITY STUDIES.pptx TG451
IN-VIVO CARCINOGENICITY STUDIES.pptx TG451
NikitaBankoti2
 
MALE REPRODUCTIVE TOXICITY STUDIES(Toxicokinetics).pptx
MALE REPRODUCTIVE TOXICITY STUDIES(Toxicokinetics).pptxMALE REPRODUCTIVE TOXICITY STUDIES(Toxicokinetics).pptx
MALE REPRODUCTIVE TOXICITY STUDIES(Toxicokinetics).pptx
KhanSabit
 
Reproductive toxicology testing
Reproductive toxicology testingReproductive toxicology testing
Reproductive toxicology testing
pp_shivgunde
 
Acute toxicity studies-425
Acute toxicity studies-425Acute toxicity studies-425
Acute toxicity studies-425
jeshicabulsara
 
Screening of anti-fertility agents.powerpointt
Screening of anti-fertility agents.powerpointtScreening of anti-fertility agents.powerpointt
Screening of anti-fertility agents.powerpointt
sujitha12341
 
laboratory animal: Rat
laboratory animal: Ratlaboratory animal: Rat
laboratory animal: Rat
Rahulprincevaja
 
animal toxicity studies.pptx
animal toxicity studies.pptxanimal toxicity studies.pptx
animal toxicity studies.pptx
DrRenuYadav2
 
Acute,Sub-acute and Sub-chronic dermal toxicity studies.pptx
Acute,Sub-acute and Sub-chronic dermal toxicity studies.pptxAcute,Sub-acute and Sub-chronic dermal toxicity studies.pptx
Acute,Sub-acute and Sub-chronic dermal toxicity studies.pptx
Dublinmatcher
 

Similar to Reproductive toxicology studies ACCORDING TO OECD guidlines 422 (20)

Reproductive toxicology
Reproductive toxicologyReproductive toxicology
Reproductive toxicology
 
Reproductive toxicology
Reproductive toxicologyReproductive toxicology
Reproductive toxicology
 
REPRODUCTIVE TOXICITY STUDIE OF MALE AND FEMALEpptx
REPRODUCTIVE TOXICITY  STUDIE OF MALE AND FEMALEpptxREPRODUCTIVE TOXICITY  STUDIE OF MALE AND FEMALEpptx
REPRODUCTIVE TOXICITY STUDIE OF MALE AND FEMALEpptx
 
DOC-20220404-WA0001..pptx
DOC-20220404-WA0001..pptxDOC-20220404-WA0001..pptx
DOC-20220404-WA0001..pptx
 
OECD guidelines-Organisation for Economic Co-operation and Development guidel...
OECD guidelines-Organisation for Economic Co-operation and Development guidel...OECD guidelines-Organisation for Economic Co-operation and Development guidel...
OECD guidelines-Organisation for Economic Co-operation and Development guidel...
 
Teratogenicity.pptx
Teratogenicity.pptxTeratogenicity.pptx
Teratogenicity.pptx
 
Female reproductive toxicity studies.pptx
Female reproductive toxicity studies.pptxFemale reproductive toxicity studies.pptx
Female reproductive toxicity studies.pptx
 
teratogenic anu-3.pptx
teratogenic anu-3.pptxteratogenic anu-3.pptx
teratogenic anu-3.pptx
 
Subacute toxicity testing as per oecd guidelines tulsi 407
Subacute toxicity testing as per oecd guidelines tulsi 407Subacute toxicity testing as per oecd guidelines tulsi 407
Subacute toxicity testing as per oecd guidelines tulsi 407
 
OECD Guideline 420: Acute oral Toxicity - Fixed Dose Procedure
OECD Guideline 420: Acute oral Toxicity - Fixed Dose ProcedureOECD Guideline 420: Acute oral Toxicity - Fixed Dose Procedure
OECD Guideline 420: Acute oral Toxicity - Fixed Dose Procedure
 
Sub acute
Sub acuteSub acute
Sub acute
 
Reproductive toxicology studies
Reproductive toxicology studiesReproductive toxicology studies
Reproductive toxicology studies
 
IN-VIVO CARCINOGENICITY STUDIES.pptx TG451
IN-VIVO CARCINOGENICITY STUDIES.pptx TG451IN-VIVO CARCINOGENICITY STUDIES.pptx TG451
IN-VIVO CARCINOGENICITY STUDIES.pptx TG451
 
MALE REPRODUCTIVE TOXICITY STUDIES(Toxicokinetics).pptx
MALE REPRODUCTIVE TOXICITY STUDIES(Toxicokinetics).pptxMALE REPRODUCTIVE TOXICITY STUDIES(Toxicokinetics).pptx
MALE REPRODUCTIVE TOXICITY STUDIES(Toxicokinetics).pptx
 
Reproductive toxicology testing
Reproductive toxicology testingReproductive toxicology testing
Reproductive toxicology testing
 
Acute toxicity studies-425
Acute toxicity studies-425Acute toxicity studies-425
Acute toxicity studies-425
 
Screening of anti-fertility agents.powerpointt
Screening of anti-fertility agents.powerpointtScreening of anti-fertility agents.powerpointt
Screening of anti-fertility agents.powerpointt
 
laboratory animal: Rat
laboratory animal: Ratlaboratory animal: Rat
laboratory animal: Rat
 
animal toxicity studies.pptx
animal toxicity studies.pptxanimal toxicity studies.pptx
animal toxicity studies.pptx
 
Acute,Sub-acute and Sub-chronic dermal toxicity studies.pptx
Acute,Sub-acute and Sub-chronic dermal toxicity studies.pptxAcute,Sub-acute and Sub-chronic dermal toxicity studies.pptx
Acute,Sub-acute and Sub-chronic dermal toxicity studies.pptx
 

More from SONALPANDE5

drugs in treatment of DIARRHEA
drugs in treatment of DIARRHEA drugs in treatment of DIARRHEA
drugs in treatment of DIARRHEA
SONALPANDE5
 
International classification of drugs and IPNP
International classification of drugs and IPNP International classification of drugs and IPNP
International classification of drugs and IPNP
SONALPANDE5
 
Spontenous adr reporting
Spontenous adr reportingSpontenous adr reporting
Spontenous adr reporting
SONALPANDE5
 
Antiemetics and prokinetics classification with mechansim
Antiemetics and prokinetics classification with mechansim Antiemetics and prokinetics classification with mechansim
Antiemetics and prokinetics classification with mechansim
SONALPANDE5
 
DRUGS IN TEREATMENT OF ULCER
DRUGS IN TEREATMENT OF ULCER DRUGS IN TEREATMENT OF ULCER
DRUGS IN TEREATMENT OF ULCER
SONALPANDE5
 
Bioassy of insulin according to Indian pharmacopoeia
Bioassy of insulin according to Indian pharmacopoeiaBioassy of insulin according to Indian pharmacopoeia
Bioassy of insulin according to Indian pharmacopoeia
SONALPANDE5
 
general and local anesthesia
general and local anesthesia general and local anesthesia
general and local anesthesia
SONALPANDE5
 
Sedatives and hypnotics
Sedatives and hypnoticsSedatives and hypnotics
Sedatives and hypnotics
SONALPANDE5
 
Infromed consent
Infromed consentInfromed consent
Infromed consent
SONALPANDE5
 
Screening of antiparkinson agent
Screening of antiparkinson agentScreening of antiparkinson agent
Screening of antiparkinson agent
SONALPANDE5
 
Neurohumoral Transmission in central nervous system
Neurohumoral Transmission in central nervous systemNeurohumoral Transmission in central nervous system
Neurohumoral Transmission in central nervous system
SONALPANDE5
 

More from SONALPANDE5 (11)

drugs in treatment of DIARRHEA
drugs in treatment of DIARRHEA drugs in treatment of DIARRHEA
drugs in treatment of DIARRHEA
 
International classification of drugs and IPNP
International classification of drugs and IPNP International classification of drugs and IPNP
International classification of drugs and IPNP
 
Spontenous adr reporting
Spontenous adr reportingSpontenous adr reporting
Spontenous adr reporting
 
Antiemetics and prokinetics classification with mechansim
Antiemetics and prokinetics classification with mechansim Antiemetics and prokinetics classification with mechansim
Antiemetics and prokinetics classification with mechansim
 
DRUGS IN TEREATMENT OF ULCER
DRUGS IN TEREATMENT OF ULCER DRUGS IN TEREATMENT OF ULCER
DRUGS IN TEREATMENT OF ULCER
 
Bioassy of insulin according to Indian pharmacopoeia
Bioassy of insulin according to Indian pharmacopoeiaBioassy of insulin according to Indian pharmacopoeia
Bioassy of insulin according to Indian pharmacopoeia
 
general and local anesthesia
general and local anesthesia general and local anesthesia
general and local anesthesia
 
Sedatives and hypnotics
Sedatives and hypnoticsSedatives and hypnotics
Sedatives and hypnotics
 
Infromed consent
Infromed consentInfromed consent
Infromed consent
 
Screening of antiparkinson agent
Screening of antiparkinson agentScreening of antiparkinson agent
Screening of antiparkinson agent
 
Neurohumoral Transmission in central nervous system
Neurohumoral Transmission in central nervous systemNeurohumoral Transmission in central nervous system
Neurohumoral Transmission in central nervous system
 

Recently uploaded

ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
Sujoy Dasgupta
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Prof. Marcus Renato de Carvalho
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
MedicoseAcademics
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
DR SETH JOTHAM
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
sisternakatoto
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
NEHA GUPTA
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Dr KHALID B.M
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 

Recently uploaded (20)

ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 

Reproductive toxicology studies ACCORDING TO OECD guidlines 422

  • 1. REPRODUCTIVE TOXICOLOGY STUDIES OECD GUIDELINES :422 Prepared by: SONAL. VIJAY. PANDE M Pharm sem 2 Department : pharmacology
  • 2. WHAT IS REPRODUCTIVE TOXICOLOGY?  Reproductive toxicity refers to structural and functional alterations that affect reproductive system in sexually mature males and females.  Reproductive toxicity includes effects on male fertility and female fertility and lactation.
  • 3. Two major class: • Reproductive toxicity -Effects on sexual behavior and fertility in males and non-pregnant females • Developmental toxicity-abnormal structure or functional development following exposure of pregnant or lactating females
  • 4. INTRODUCTION ESTROUS CYCLE: Reproductive cycle of female, generally defined as period from one estrus to the next. ESTRUS: Period of sexual receptivity. • Commonly referred to as “Heat” ANESTRUS: Period when female does not experience cycles • Occurs during pregnancy.
  • 5. Polyestrus: Uniform distribution of estrous cycles which occur regularly throughout the year eg: rodents, cattle Monoestrus: – One cycle per year Eg: dogs, wolf,bears
  • 6. Estrous cycle Follicular phase Luteal phase Begins during luteolysis Ends at ovulation Proestrus Estrus Begins during ovulation Ends at luteolysis Metestrus Diestrus
  • 7. The oestrous cycle consists of four stages: 1.Prooestrus 2.oestrus 3.metestrus (or dioestrus 1) 4.dioestrus (or dioestrus 2). • Because rats are continuously polyoestrous (i.e., cycle constantly throughout the year) dioestrus is immediately followed by the prooestrus phase of the next cycle • Anoestrus, a period of reproductive quiescence between oestrous cycles, is thus not usually observed in healthy, cycling female rats. • Oestrous cyclicity only ceases during pseudopregnancy, pregnancy, and lactation, although a fertile postpartum oestrus does occur within 24 hours after birth.
  • 8. Proestrus • Begins when progesterone declines(luteolysis:regression of corpus luteum ) and ends at onset of estrus • Lasts 2 to 5 days Estrus • Period of sexual receptivity • Large increase in estrogen Metestrus: ↑Increase in progesterone, ↆ decrease in estrogen • Endometrial lining thickens and uterine muscles show increased development. Diestrus: Relatively short period of time between estrous cycles during the breeding season of polyestrous animals – No reproductive activity
  • 9. • Sexual maturity in female rats usually occurs between 30 and 50 days of age. • The occurrence of vaginal opening (VO) and first oestrus, as 38 days. • The first oestrous cycle begins within approximately one week after vaginal opening and recurs regularly every 4 or 5 days for a variable proportion of the animal’s lifespan, depending on the strain of rat.
  • 10.
  • 11. duration of an ovarian cycle can vary: 4 days: mice, rats and hamsters 16 days: guinea pigs 28 days: humans
  • 12.
  • 13.
  • 14. Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test OECD guideline for testing of chemicals on reproductive toxicology
  • 15. PRINCIPLE OF THE TEST:  The test chemical is administered in graduated doses to several groups of males and females.  Males should be dosed for a minimum of four weeks and up to and including the day before scheduled kill  pre-mating dosing period in males, fertility may not be a particular sensitive indicator of testicular toxicity.
  • 16.  Therefore, a detailed histological examination of the testes is essential.  Histopathology of the male gonads, is considered sufficient to enable detection of the majority of effects on male fertility and spermatogenesis.  Females should be dosed throughout the study.  This includes mating, the duration of pregnancy and at least thirteen days after delivery, up to and including the day before scheduled kill.
  • 17.  Duration of study, following acclimatisation and pre-dosing oestrous cycle evaluation, is dependent on the female performance and is approximately 63 day. [at least 14 days pre-mating, (up to) 14 days mating, 22 days gestation, 13 days lactation].
  • 18. DESCRIPTION OF THE METHOD Selection of animal species Guideline is designed for use with the rat. The rat was the only species used. The test animals should be characterized as to species, strain, sex, weight and age. Weight variation of animals used should be minimal and not exceed 20% of the mean weight of each sex.  Animals from the same strain and source are used in both studies.
  • 19. HOUSING AND FEEDING  The temperature in the experimental animal room should be 22º C (± 3). relative humidity should be at least 30%  Lighting should be artificial, the photoperiod being 12 hours light, 12 hours dark.  For feeding, laboratory diets used with an unlimited supply of drinking water.
  • 20.  no more than five animals should be housed per cage.  Pregnant females should be caged individually and provided with nesting materials.  Lactating females will be caged individually with their offspring.
  • 21. PREPARATION OF THE ANIMALS  Healthy young adult animals are randomly assigned to the control and treatment groups.  Cages should be arranged in such a way that possible effects due to cage placement are minimized.  The animals are uniquely identified and kept in their cages for at least five days prior to the start of the study to allow for acclimatisation to the laboratory conditions.
  • 22. PREPARATION OF DOSES The test chemical be administered orally unless other routes of administration are considered more appropriate. When the oral route is selected, the test chemical is usually administered by gavage. The test chemical is dissolved or suspended in a suitable vehicle. PROCEDURE:  Number and sex of animals • It is recommended that each group be started with at least 10 males and 12-13 females.
  • 23.  Dosage • Generally, at least three test groups and a control group should be used. • Dose levels may be based on information from acute toxicity tests or on results from repeated dose studies. • If a vehicle is used in administering the test chemical, the control group should receive the vehicle in the highest volume used. • Dose levels should be selected taking into account any existing toxicity and (toxico-) kinetic data available.
  • 24. • It should also be taken into account that there may be differences in sensitivity between pregnant and non-pregnant animals. • The highest dose level should be chosen with the aim of inducing toxic effects but not death nor obvious suffering. • Thereafter, a descending sequence of dose levels should be selected with a view to demonstrating any dosage related response and no adverse effects at the lowest dose level. • Two- to four- fold intervals are frequently optimum and addition of a fourth test group is often preferable to using very large intervals (e.g. more than a factor of 10) between dosages.
  • 25. Administration of doses • The animals are dosed with the test chemical daily for 7 days a week. • The volume should not exceed 1 ml/100 g body weight, except in the case of aqueous solutions where 2 ml/100 g body weight may be used. • Except for irritating or corrosive test chemicals which will normally reveal exacerbated effects with higher concentrations, variability in test volume should be minimized by adjusting the concentration to ensure a constant volume at all dose levels. • For test chemical administered via the diet or drinking water, it is important to ensure that the quantities of the test chemical involved do not interfere with normal nutrition or water balance.
  • 27. EXPERIMENTAL SCHEDULE  Dosing of both sexes should begin at least 2 weeks prior to mating, after they have been acclimatised for at least five days and females have been screened for normal oestrous cycles.  The study should be scheduled in such a way that oestrous cycle evaluation begins soon after the animals have attained full sexual maturity.  This may vary slightly for different strains of rats in different laboratories, e.g. Sprague Dawley rats 10 weeks of age, Wistar rats about 12 weeks of age
  • 28.  Dams with offspring should be killed on day 13 post-partum, or shortly thereafter. In order to allow for overnight fasting of dams prior to blood collection (if this option is preferred), dams and their offspring need not necessarily be killed on the same day.  The day of birth (viz. when parturition is complete) is defined as day 0 post- partum  Dosing is continued in both sexes during the mating period.
  • 29.  Males should further be dosed after the mating period at least until the minimum total dosing period of 28 days has been completed  They are then killed, or, alternatively, are retained and continued to be dosed for the possible conduction of a second mating if considered appropriate.  Daily dosing of the parental females should continue throughout pregnancy.
  • 30. Mating procedure: Normally, 1:1 (one male to one female) matings should be used in this study.  Each morning the females should be examined for the presence of sperm or a vaginal plug.  Day 0 of pregnancy is defined as the day on which mating evidence is confirmed
  • 31. IN LIFE OBSERVATIONS Clinical observation:  Throughout the test period, general clinical observations should be made at least once a day, and more frequently when signs of toxicity are observed.  They should be made preferably at the same time(s) each day. all signs of toxicity, including mortality, should be recorded.  These records should include time of onset, degree and duration of toxicity signs.
  • 32. Body weight and food/water consumption  Males and females should be weighed on the first day of dosing, at least weekly thereafter, and at termination.  During pregnancy, females should be weighed on days 0, 7, 14 and 20.
  • 33. Oestrous cycles  Oestrous cycles should be monitored before treatment starts to select for the study females with regular cycle.  Vaginal smears should also be monitored daily from the beginning of the treatment period until evidence of mating. If there is concern about acute stress effects that could alter oestrous cycles.
  • 34. Offspring parameters:  The duration of gestation should be recorded and is calculated from day 0 of pregnancy.  Any abnormal behaviour of the offspring should be recorded.
  • 35. Clinical biochemistry  Blood samples from a defined site are taken.  Plasma samples specifically for hormone determination should be obtained at a comparable time of the day.  The numerical value obtained when analysing hormone concentration.
  • 36. Pathology Gross necropsy :  At the time of sacrifice or death during the study, the adult animals should be examined macroscopically for any abnormalities or pathological changes.  Vaginal smears should be examined in the morning on the day of necropsy to determine the stage of the oestrous cycle and histopathology of ovaries.  The testes and epididymides of all male adult animals should be weighed.
  • 37. Histopathology:  Histological examination should be performed on the ovaries, testes and epididymides of the animals of the highest dose group and the control group.
  • 38. DATA AND REPORTING • Individual animal data should be provided. • Additionally, all data should be summarised in tabular form, showing for each test group the number of animals at the start of the test, the number of animals found dead during the test or killed • The time of any death or humane kill, the number of fertile animals, the number of pregnant females, • the number of animals showing signs of toxicity, a description of the signs of toxicity observed.
  • 39. Evaluation of results: • The findings of this toxicity study should be evaluated in terms of the observed effects, necropsy and microscopic findings. Test report :  Test chemical: - source, limit date for use, if available stability of the test chemical physical appearance, water solubility, and additional relevant physicochemical properties; Vehicle
  • 40.  Test animals: o species/strain used; o number, age and sex of animals; o source, housing conditions, diet, etc.; o individual weights of animals at the start of the test.  Results: o body weight/body weight changes; o food consumption, and water consumption if available; o toxic response data by sex and dose, including fertility, gestation, and any other signs of toxicity;
  • 42. FEMALE FERTILITY TEST • Drugs administered to both males (28days)and female (14 days) before mating Segment I : Fertility and general reproductive performance study Segment II: Teratogenicity Segment III: Prenatal and post-natal study perinatal : fertility and early embryonic development
  • 43. FEMALE FERTILITY STUDY (SEGMENT I): • The study should be done in one rodent species (rat preferred). • The drug should be administered to both males and females, beginning a sufficient number of days (28 days in males and 14 days in females) before mating. • Drug treatment should continue during mating and, subsequently, during the gestation period.
  • 44. • Three graded doses should be used, the highest dose (usually the MTD obtained from previous systemic toxicity studies) should not affect general health of the parent animals, At least 15 males and 15 females should be used per dose group. • Control and the treated groups should be of similar size. • The route of administration should be the same as intended for therapeutic use
  • 45. •Dams should be allowed to litter and their medication should be continued till the weaning of pups. • Observations on body weight, food intake, clinical signs of intoxication, mating behaviour, progress of gestation! parturition periods, length of gestation, parturition, post-partum health and gross pathology (and histopathology of affected organs) of dams should be recorded.
  • 46. •The pups from both treated and control groups should be observed for general signs of intoxication, sex-wise distribution in different treatment groups, body weight, growth parameters, survival, gross examination, and autopsy. •Histopathology of affected organs should be done.
  • 49. PERINATAL STUDY (SEGMENT III): • This study is specially recommended if the drug is to be given to pregnant or nursing mothers for long periods or where there are indications of possible adverse effects on foetal development. • One rodent species (preferably rat) is needed. Dosing at levels comparable to multiples of human dose should be done by the intended clinical route. • At least 4 groups (including control), each consisting of 15 dams should be used.
  • 50. • The drug should be administered throughout the last trimester of pregnancy (from day 15 of gestation) and then the dose that causes low foetal loss should be continued throughout lactation and weaning. • Dams should then be sacrificed and examined as described below.
  • 51. • One male and one female from each litter of Fl generation (total 15 males and 15 females in each group) should be selected at weaning and treated with vehicle or test substance (at the dose levels described above) throughout their periods of growth to sexual maturity, pairing, gestation, parturition and lactation. • Mating performance and fertility of FI generation should thus be. evaluated to obtain the F2 generation whose growth parameters should be monitored till weaning. • The criteria of evaluation should be the same as described earlier.
  • 52. • Animals should be sacrificed at the end of the study and the observation parameters should include (Dams) body weight, food intake, general signs of intoxication, progress of gestation / parturition periods and gross pathology (if any);andfor pups, the clinical signs, sex-wise distribution in dose groups, body weight, growth parameters, gross examination, survival and autopsy (if needed) and where necessary, histopathology.
  • 54.
  • 55. • Estrous female rats at 10 to 11 weeks of age were cohabited overnight with a single male. • The next morning, females with sperm in their vaginal smears were regarded as pregnant, and this day was designated as day 0 of gestation. • Once insemination was confirmed, the females were weighed and randomly allocated to six experimental groups. • The dams were allowed to deliver naturally and nurse their pups until postnatal day (PND) 21. • On PND 0 (the day of birth), all pups were weighed and their sex was determined, and the litters were culled randomly to eight (four pups/sex/ litter when possible) PROCEDURE
  • 56. • In the present study, three to five males and three to five females per litter were used. • All neonates were given daily gavage administration of 12.5, 25, 50, or 100 mg/kg genistein. • The measurement of sexual organ weight and histopathologic observation of the reproductive tracts were performed

Editor's Notes

  1. 422 Adopted: 29 July 2016 © OECD, (2016) You are free to use this material subject to the terms and conditions available at http://www.oecd.org/termsandconditions/. This Guideline was adopted by the OECD Council by written procedure on 29 July 2016 [C(2016)103]. OECD GUIDELINE FOR TESTING OF CHEMICALS Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test